Skip to content

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

Prasinezumab is an investigational treatment for Parkinson’s Disease (PD). The PADOVA trial (NCT04777331) is a Phase 2b, multicentre, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety/tolerability of prasinezumab in individuals with early-stage PD on stable symptomatic therapy. This poster focuses on the rationale, study design and baseline characteristics of the PADOVA study population.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically